A tighter archive for life-science signals.
Search once, then narrow by source or topic.
Sarepta CEO Doug Ingram to retire after a decade of Duchenne breakthroughs and controversies
Sarepta CEO Doug Ingram to retire after a decade of Duchenne breakthroughs and controversies
Analysts see potential in MDMA drug after AtaiBeckley reports improvements in anxiety trial
Analysts see potential in MDMA drug after AtaiBeckley reports improvements in anxiety trial
Boehringer pens $500M pact with British biotech for oral approach to autoimmune diseases
Boehringer pens $500M pact with British biotech for oral approach to autoimmune diseases
Bristol Myers' $800M ADC hits primary survival endpoints in phase 3 breast cancer trial
Bristol Myers' $800M ADC hits primary survival endpoints in phase 3 breast cancer trial
Quantum Surgical snaps up J&J's NeuWave Medical for its microwave ablation technology
Quantum Surgical snaps up J&J's NeuWave Medical for its microwave ablation technology
Protagonist plans to pocket $400M from Takeda rather than split US rusfertide profits
Protagonist plans to pocket $400M from Takeda rather than split US rusfertide profits
Accent halts solid tumor trial over adverse events, pivots to other lead cancer program
Accent halts solid tumor trial over adverse events, pivots to other lead cancer program
Asahi Kasei scoops up Germany's Aicuris for $920M in R&D portfolio boost
Asahi Kasei scoops up Germany's Aicuris for $920M in R&D portfolio boost
ARPA-H designates up to $144M for anti-aging medical research
ARPA-H designates up to $144M for anti-aging medical research
Worried Trump's MFN push will ‘destroy biotech innovation,’ midsize companies form coalition to fight back
Worried Trump's MFN push will ‘destroy biotech innovation,’ midsize companies form coalition to fight back
Charles River sells manufacturing and discovery businesses to fulfill promised pivot
Charles River sells manufacturing and discovery businesses to fulfill promised pivot
Novo Nordisk inks $2.1B pact with Langer startup to boost oral drug delivery prowess
Novo Nordisk inks $2.1B pact with Langer startup to boost oral drug delivery prowess
After gene therapy exit, Pfizer locks in global license for Beam gene editing candidate
After gene therapy exit, Pfizer locks in global license for Beam gene editing candidate
GSK pays $950M in cash for Canadian biotech and its Winrevair-like blood pressure drug
GSK pays $950M in cash for Canadian biotech and its Winrevair-like blood pressure drug
After 230% deal size explosion, China is no longer the 'bargain basement' for biopharma licensing: analyst
After 230% deal size explosion, China is no longer the 'bargain basement' for biopharma licensing: analyst
Werewolf weighs sale or merger as cash reserves whimper
Werewolf weighs sale or merger as cash reserves whimper
Evinova reels in AI clinical development deals with Astellas and AstraZeneca
Evinova reels in AI clinical development deals with Astellas and AstraZeneca
FDA freezes enrollment in MacroGenics cancer trial after patient death
FDA freezes enrollment in MacroGenics cancer trial after patient death
Brand directory, kept in view
A rolling strip of the companies, platforms, CROs and device makers that show up across the coverage.
Open about page